Kailera Initiates Another Ph2 Ribupatide Study; Ascletis Reports Topline Ph2 Data; Laekna Announces Topline Ph1 Data; Glooko Connects with Roche’s CGM; SK pharmteco to Manufacture Long-Acting API for Current Lilly Product; Novo Acknowledges FDA Form 483
A series of cardiometabolic-related news items has been observed from Kailera, Ascletis Pharma, Laekna, Glooko, SK pharmteco, and Novo Nordisk. Below, FENIX provides highlights and insights into the respective news items.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.